Watch obesity treatment go mainstream and holistic
Industry Buzz
Patients used to come in asking for 'weight loss shots,' now they're asking about insulin resistance, inflammatory markers, and cardiovascular risk reduction. The public figure transparency around GLP-1s has normalized what should have always been a metabolic health discussion, not a vanity project.
—Giselle Prado-Wright, MD
Patients feel better metabolically, but then notice rapid facial volume loss, skin laxity, or an aged appearance that does not match how healthy they feel. This creates a tension between health gains and perceived aging, [which] reflects a more mature understanding of these medications.
—Steven Pearlman, MD, FACS, dual board-certified facial plastic surgeon
When an elite athlete like Serena Williams describes GLP-1 therapy as “the medicine my body needed,” physicians recognize the language as something they use during cardiology and endocrinology consultations, not in weight loss clinics.[]
Patients increasingly describe goals tied to cholesterol, inflammation, joint load, and cardiovascular risk rather than weight alone. This shift aligns with how clinicians are evaluating treatment success.
Serena Williams’ appearance in Ro’s first Super Bowl ad signaled a turning point in how GLP-1 therapy is framed: away from cosmetic weight loss and toward measurable health outcomes. The “Healthier on Ro” campaign avoided aspirational imagery and instead highlighted clinical markers, with Williams citing improvements in cholesterol, weight, and cardiovascular risk.
Her credibility is helping position obesity treatment as preventive medicine, aligned with lipid management and cardiometabolic care, reflecting how clinicians now discuss these therapies with patients. In contrast to years of cautious pharma advertising, Serena’s presence suggested growing confidence that GLP-1s have entered mainstream, trust-based medical care.
Beyond weight loss: The shift from cosmetic to preventive
This message resonates with physicians because GLP-1 therapy has matured beyond cosmetic benefits. Survey data—published in the Journal of Cardiovascular Development and Disease—examining clinicians’ perspectives on GLP-1 therapy found greater physician confidence when benefits were framed around cardiovascular and metabolic outcomes rather than weight loss alone.[]
According to cosmetic surgeon Giselle Prado-Wright, MD, patients now frame GLP-1 therapy in terms of metabolic health rather than cosmetic weight loss. “It's a conversation shift I've witnessed dramatically accelerate in the past 18 months. Patients used to come in asking for 'the weight loss shot'—now they're asking about insulin resistance, inflammatory markers, and cardiovascular risk reduction. The public figure transparency around GLP-1s has normalized what should have always been a metabolic health discussion, not a vanity project," she says.
However, as Steven Pearlman, MD, FACS, a dual board-certified facial plastic surgeon, notes, “Appearance still matters—even when patients say it does not. As a facial plastic surgeon, I often see the downstream effects first. Patients feel better metabolically, but then notice rapid facial volume loss, skin laxity, or an aged appearance that does not match how healthy they feel. This creates a tension between health gains and perceived aging. The conversation has evolved from, ‘How much weight will I lose?’ to, ‘How do I lose weight without losing my face?’ That reflects a more mature understanding of these medications.”
Top takeaways for patient counseling
The “holistic” conversation now extends to musculoskeletal and functional health. Patients initiating GLP-1 therapy increasingly ask about muscle mass, injury risk, and strength preservation.[] Media coverage has amplified concern around lean mass loss, pushing clinicians to integrate resistance training, protein intake targets, and functional assessments into treatment plans.
According to Dr. Pearlman, counseling physically active or athletic patients on lean mass preservation during GLP-1 treatment is one of the most important things a physician can do. “GLP-1s reduce appetite, but they do not discriminate between fat and lean mass. For athletic or physically active patients, protein intake, resistance training, and pacing …weight loss are nonnegotiable. I encourage slower titration, adequate protein, and consistent strength training to preserve muscle and facial support structures. From a facial standpoint, muscle and soft-tissue volume matter for long-term aging. Losing weight too quickly can accelerate visible aging even in very fit individuals,” he says. To preserve lean mass in physically active or athletic patients, says Vivek Gupta, MD, MPH, a board-certified internal medicine physician, “We measure body composition and advise at least 1–1.5g/kg protein to mitigate lean tissue loss and maximize fat loss. We also use the GLPs in combination with working on nutrition, physical activity, sleep, and stress to create sustainable lifestyle changes and ensure overall improvement in our patients' holistic health."
Is it right to call GLP-1 therapy a holistic medicine?
Not exactly—especially when patients seek consultation because they’re motivated by public figures rather than a medical referral. “Social media often frames GLP-1s as anti-aging or longevity drugs, which is not supported by human data,” Dr. Pearlman says. “I explain that the survival benefits we see are in patients with obesity and cardiometabolic disease, not healthy individuals seeking optimization. I also emphasize that any off-label or speculative use should be approached cautiously and transparently. From my perspective, the goal is alignment: aligning metabolic health, physical function, and appearance, rather than chasing trends driven by celebrities or internet narratives.”